Mark P. Schoenberg, MD
The investigational mitomycin formulation UGN-101 (mitomycin gel) demonstrated a 57% complete response (CR) rate in patients with low-grade upper-tract urothelial cancer (UTUC), according to topline findings from the ongoing phase III OLYMPUS trial (NCT02793128).1
At the time 6 patients underwent 3-month follow-up and remained in CR.
- UroGen Pharma Announces Positive Results of UGN-101 from Pivotal Phase 3 OLYMPUS Trial for the Non-Surgical Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC). UroGen Pharma Ltd. Published January 8, 2019. https://bit.ly/2LX0ogq?rel=0" . Accessed January 8, 2019.
- Kleinmann N, Pierorazio P, Matin S, et al. Non-surgical management of low grade upper tract urothelial cancer: an interim analysis of the international multicenter OLYMPUS trial (NCT02793128). J Urol. 2018;199(4S):e1166. doi: 10.1016/j.juro.2018.03.097.
... to read the full story